NCT00856271
Completed
Phase 3
A Randomized, Double-blind, Double-dummy, Multi-center Study to Investigate the Safety and Efficacy of Olmesartan Medoxomil Compared With Losartan Potassium in Patients With Mild to Moderate Essential Hypertension
ConditionsEssential Hypertension
Overview
- Phase
- Phase 3
- Intervention
- losartan potassium
- Conditions
- Essential Hypertension
- Sponsor
- Daiichi Sankyo
- Enrollment
- 287
- Primary Endpoint
- Change of trough seated diastolic blood pressure from baseline to 8 weeks
- Status
- Completed
- Last Updated
- 15 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of olmesartan medoxomil compared with losartan potassium in patients with mild to moderate essential hypertension.
Investigators
Eligibility Criteria
Inclusion Criteria
- •mild to moderated essential hypertension (mean seated diastolic blood pressure ≥ 95 mmHg and \<110 mmHg, mean seated systolic blood pressure \< 180 mmHg)
- •able to give written informed consent
Exclusion Criteria
- •known or suspected secondary hypertension
- •history of chronic hepatic diseases
- •obstructive hypertrophic cardiomyopathy/clinically significant valvular heart disease
- •cardiac arrhythmia
- •unstable angina pectoris
- •congestive heart insufficiency (New York Heart Association classification III-IV)
- •bilateral renal artery stenosis
- •isolated renal artery stenosis
- •post renal transplantation
- •history of acute myocardial infarction/percutaneous transluminal coronary angioplasty or heart surgery within three months before enrollment
Arms & Interventions
2
losartan potassium
Intervention: losartan potassium
1
olmesartan medoxomil
Intervention: olmesartan medoxomil
Outcomes
Primary Outcomes
Change of trough seated diastolic blood pressure from baseline to 8 weeks
Time Frame: Baseline to 8 weeks
Similar Trials
Completed
Phase 3
Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential HypertensionEssential HypertensionNCT00872586Daiichi Sankyo304
Completed
Phase 3
A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established AtherosclerosisAtherosclerosisNCT00382213Daiichi Sankyo210
Completed
Not Applicable
Assessment of the Effectiveness of OLMETEC® and OLMETEC PLUS® for Treatment of Hypertension in Stage I and II Patients (Study P05254)(COMPLETED)HypertensionNCT00811226Schering-Plough450
Active, not recruiting
Phase 1
The efficacy and safety of olmesartan medoxomil/amlodipine fixed combination in patients with mild to moderately elevated blood pressure. An international randomized, double-blind, 10-week clinical InvestigatioEUCTR2014-003470-17-ROKrka, d.d. Novo mesto997
Active, not recruiting
Phase 1
The efficacy and safety of olmesartan medoxomil/amlodipine fixed combination in patients with mild to moderately elevated blood pressure. An international randomized, double-blind, 10-week clinical InvestigatioPrimary arterial hypertensionMedDRA version: 17.1Level: LLTClassification code 10020775Term: Hypertension arterialSystem Organ Class: 100000004866Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2014-003470-17-DEKrka, d.d. Novo mesto800